{"title":"Off-the-shelf CAR T cells for refractory autoimmunity","authors":"Maria Papatriantafyllou","doi":"10.1038/s41584-024-01148-y","DOIUrl":null,"url":null,"abstract":"Early data indicate that allogeneic CAR T cell therapy targeting B cells is a scalable and safe therapeutic strategy in refractory autoimmunity.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"20 9","pages":"527-527"},"PeriodicalIF":29.4000,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41584-024-01148-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Early data indicate that allogeneic CAR T cell therapy targeting B cells is a scalable and safe therapeutic strategy in refractory autoimmunity.
期刊介绍：
Nature Reviews Rheumatology is part of the Nature Reviews portfolio of journals. The journal scope covers the entire spectrum of rheumatology research. We ensure that our articles are accessible to the widest possible audience.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
